Background. An important question for chlamydia control programs is the extent to which finding and treating prevalent, asymptomatic Chlamydia trachomatis genital infection reduces reproductive sequelae in infected women.
ial infections reduces the incidence of reproductive tract sequelae in infected women. Many uncertainties remain about the natural history of untreated C. trachomatis infection in leading to sequelae, as Haggerty et al discuss in this supplement [3] . One of the most important factors affecting the potential effectiveness of chlamydia control programs is the timing of tubal inflammation and damage relative to the acquisition of infection. This timing profoundly impacts the likelihood that infections can be identified and treated before development of short-term sequelae, such as symptomatic pelvic inflammatory disease (PID), and before development of tubal damage that may ultimately lead to long-term sequelae, such as tubal factor infertility and ectopic pregnancy. There is little doubt that C. trachomatis infection can lead to sequelae [4] and that chlamydial infection can be effectively treated with available antibiotics [5] . What is less clear, however, is the degree to which treatment given at various times during the natural course of infection can interrupt progression to sequelae.
The duration of genital C. trachomatis infection in the absence of treatment has not been completely elucidated [6] , but available long-term studies suggest that a typical untreated chlamydial infection can last a year or longer [7, 8] . Thus, asymptomatic C. trachomatis infections may have been present for many months when detected by screening. By assuming that women acquire new chlamydial infections at a steady rate between screenings and that women are screened consistently at 1-year intervals, the mean duration of each chlamydia infection detected would be 6 months. With longer screening intervals, as frequently occurs in the United States [9] , duration of infection could be greater. If acute PID and/or tubal damage primarily occur very soon after acquisition of C. trachomatis infection, screening will only affect that small proportion of the infected population who have recently acquired infection. Screening at less frequent intervals would result in even fewer women receiving benefit. If, however, tissue-damaging pathologic processes are mainly initiated later in the course of infection or continue to be elicited by ongoing infection over an extended period of time, screening would benefit a greater proportion of infected women.
In preparation for the April 2008 Chlamydia Immunology and Control Expert Advisory Meeting, we reviewed and critically evaluated evidence for the effectiveness of chlamydia screening in reducing the incidence of sequelae in screened women. We assessed this evidence in the context of achieving better understanding of chlamydial natural history and pathogenesis; thus, we focused primarily on the role of screening in interrupting progression to upper tract inflammation and sequelae in already infected women. We did not explore the effect of screening or other control efforts in reducing transmission of C. trachomatis in a population, which could prevent sequelae by preventing new incident chlamydial infections in women in the population. This evidence has recently been reviewed elsewhere [10] . Our goals were to assess what is known about screening and treatment to prevent sequelae in already infected women, to delineate remaining gaps in knowledge that have implications for chlamydia control programs, and to outline the most important research needs to fill those gaps.
METHODS
We conducted a search of the English-language literature from 1960 through March 2008 with use of the Medline computerized database of the US National Library of Medicine. The Medical Subject Headings and free text terms "chlamydia," "Chlamydia trachomatis," and "chlamydia infections" (exploded) were combined with the terms "pelvic inflammatory disease," "salpingitis," "endometritis," "infertility," and "ectopic pregnancy" (exploded) and then limited to humans and persons у13 years of age. The search excluded articles focused primarily on "Chlamydophila pneumoniae." We also searched reference lists of articles to identify potential additional references.
We included original, prospective studies of chlamydia screening interventions in women that had any of the following primary outcomes: PID, infertility, or ectopic pregnancy. We also included registry-based retrospective cohort studies and ecological studies if they discussed one of the primary outcomes in relation to chlamydia testing. We did not include crosssectional and case-control studies, nor did we include studies with a primary outcome of screening coverage, chlamydia prevalence or incidence, or adverse pregnancy outcomes other than ectopic pregnancy. We also excluded articles that assessed screening and outcomes after therapeutic abortion or other surgical instrumentation.
RESULTS
Our initial literature search yielded 875 unique citations. After review by an author (S.G.) for the aforementioned inclusion criteria, a total of 11 articles were selected for critical evaluation: 2 randomized controlled trials [11, 12] and 1 nonrandomized cohort study [13] that evaluated chlamydia screening interventions and clinical PID outcomes; 4 registry-based retrospective cohort studies evaluating chlamydia testing and longterm outcomes, including ectopic pregnancy [14] [15] [16] [17] and infertility [17] ; and 4 ecological studies of rates of chlamydia infection and either PID [18] [19] [20] or ectopic pregnancy outcomes (Table 1) [18, 21] . We identified no randomized or nonrandomized trials of the effect of chlamydia screening on subclinical tubal inflammation, tubal scarring, or the long-term outcomes of ectopic pregnancy and tubal factor infertility. We present the results according to study methods.
Randomized controlled trials. A randomized controlled trial by Scholes et al [12] is the study cited most widely, including by the US Preventive Services Task Force [22] , as providing evidence for the individual benefits of screening. In this study involving 2607 young women at high risk in a Seattlearea health maintenance organization (HMO) population, a 1-time proactive approach of inviting women for chlamydia screening (64% were tested) significantly reduced the risk of subsequent PID by ∼50% over the next year, compared with a control group not invited for testing (relative risk, 0.44; 95% confidence interval, 0.20-0.88). At the time of this review, these data remain the best available on the benefits of screening to prevent PID in infected women. However, some aspects of this trial raise questions as to whether the magnitude of observed benefits is generalizable and provides realistic expectations of benefit in real-world settings.
First, only 7% of the 36,547 women who were randomized 
S159
Cohort studies with untested control group Clark et al [13] were ultimately enrolled. Women aged 18-34 years who were registered with the HMO were randomized to screening and control groups and then sent a survey to determine study eligibility based on a risk score (Table 1 ). The authors reported more aggressive contacting of survey nonresponders from the intervention group to expedite testing appointments after eligibility determination. This may have resulted in the observed 1:1.6 ratio instead of the expected 1:2 ratio between the intervention and control groups, introducing the possibility of selection bias. It is not clear how such a selection bias might affect estimation of screening benefits, but randomization may have been compromised. Second, by applying the rate of PID in the control group to person-months in the intervention group, we would expect 21 cases of PID, but only 9 cases were observed. Thus, 12 cases of PID were apparently prevented by treating 44 women, suggesting that at least 27% of the infections identified by screening would have progressed to diagnosed PID without any intervention. This figure appears substantially higher than findings from other studies of asymptomatic populations undergoing screening who were followed up untreated for 12 months [3, 8] . In addition, C. trachomatis has been implicated in ∼30% of acute PID cases [23] ; thus, even if all chlamydia-associated cases of PID were prevented by screening, a 50% decrease is larger than what might be expected on the basis of previous studies.
Østergaard et al [11] conducted a cluster randomized trial of 17 high schools in a Danish county, in which students in intervention schools were offered 1-time screening of homecollected specimens for C. trachomatis and students in control schools were given referral information about clinic-based testing. Less than half of the students returned eligibility surveys. Because 93% of participating students in the intervention group had C. trachomatis testing performed, compared with only 8% of control students, the effect of screening could be evaluated. Female students were followed up in 1 year, and incident PID was assessed by self-report, with confirmation by pharmacy records. Outcome assessment was unblinded, and almost 50% of students were lost to follow-up; thus, this study had a substantial number of limitations. Nonetheless, it had findings similar to those from the trial by Scholes et al [12] . The 1-time screening approach in the Danish study was associated with a halving of PID occurrence over 1 year (4.2% vs 2.1%; P p ). Testing of 867 female students and detection of 43 in-.045 fections prevented 9 reported cases of PID among the 443 interviewed students at follow-up. Unlike Scholes et al [12] , Østergaard et al [11] also screened boys attending the same schools, and this may have had an impact on community transmission, preventing some new infections and reinfections that could have also led to PID.
Cohort studies. An impact of the magnitude found in these 2 randomized controlled trials should be easy to detect. However, a large cohort study of chlamydia screening in female US Army recruits by Clark et al [13] did not reproduce these findings. In this study, a total of 7053 women participating in a screening program on Sundays at a basic training intake center were tested and treated for C. trachomatis infection, and 21,021 women who arrived on different days were not. These women were followed up for hospitalizations over a mean of 1.5 years with use of US Army coded administrative data. There were no significant differences between the screened and unscreened groups in hospitalization rates for chlamydia-related outcomes (PID, infertility, or ectopic pregnancy). This study was not randomized and was limited by lack of outpatient data, which is a large concern because, at the time of the study, most PID cases were treated in the outpatient setting [24] . However, it does raise the issue that the positive effects of screening may be difficult to ascertain and dependent on the population, and suggests the effect may be weaker than that observed by Scholes et al [12] , at least in some populations. The 2 randomized controlled trials and the study by Clark et al [13] used symptomatic, clinically diagnosed PID as the study outcome. No randomized trials have directly evaluated the effect of chlamydia screening on ectopic pregnancy and infertility, conditions that may not be observed for several years, in part because young women's use of contraception to prevent unplanned pregnancy delays their diagnosis. Three historical cohort studies in Scandinavian countries and a study in Wisconsin used clinical and population registers to link C. trachomatis testing records with data on long-term complications [14] [15] [16] [17] . These studies, the findings of which are summarized in Table 1 , yield useful information on the risk of long-term complications in women with at least 1 diagnosed and treated C. trachomatis infection but provide little insight on the role of screening in preventing these complications.
Only one of the historical cohort studies, the Swedish study by Low et al [17] , had information about a comparison group of women who had never been tested for chlamydia. This group had lower rates of PID and infertility diagnoses than did women who were tested, including women who only had negative chlamydia test results. This highlights the fact that, outside a randomized trial, women who have not been tested are likely to be different and probably at lower risk of chlamydial infection, compared with those who have been tested. Another methodological issue affecting interpretation of these studies relates to undetected infections. The intensity of C. trachomatis testing and control has been greater in the 3 Scandinavian countries in which the cohort studies were done than in most other European countries [2] . Nonetheless, data reported in the Norwegian and Swedish studies show that most women had only 1-2 tests performed over a 10-14-year period [15, 17] ; therefore, there is a high likelihood of undetected infections at other times. Because C. trachomatis is associated with high rates of repeat infection [25, 26] , women with 1 detected chlamydial infection are particularly likely to have had у1 other undetected, untreated infection. This would tend to reduce the observed impact of testing on subsequent long-term sequelae. All in all, it is difficult to make an unbiased assessment of the benefits of screening using these types of observational data.
Ecological studies. Ecological studies have been cited as showing the effectiveness of screening programs, based on coincident decreases in chlamydia and chlamydia-related outcomes observed in regions that were the earliest to initiate chlamydia control efforts (Table 1) [18, 19, 21] . During the 1980s and early 1990s, when chlamydia control activities were being implemented, rates of identified chlamydial infection decreased in conjunction with rates of PID [18, 19] and ectopic pregnancy [18, 21] . However, in some areas, PID rates appeared to be decreasing before the chlamydia control programs started [18, 19] , and many factors, such as decreases in the number of gonorrhea infections, increases in safer sex with the human immunodeficiency virus (HIV) epidemic, and better diagnosis and treatment of symptomatic C. trachomatis infection, occurred at a similar time. Since the late 1990s in Australia, outpatient clinical encounter rates for PID have continued to decrease among young women, whereas rates of reported chlamydia cases have increased substantially [20] . Similar findings have been observed in British Columbia [27] . Chlamydia control programs may well be contributing to ongoing decreases in chlamydia-associated sequelae, but ecological studies cannot be used to determine causality.
DISCUSSION
Summary of existing data. Only a few studies have evaluated the direct benefits of screening for C. trachomatis genital infection. Two randomized controlled trials of 1-time screening for chlamydial infection-in a Seattle-area HMO and a Danish school district-revealed an ∼50% reduction in the incidence of PID among screened women in the following year. However, both of these trials had methodological issues that may have affected the magnitude of observed screening benefits in the populations evaluated and that might limit the generalizability of these findings to real-world settings. A large, nonrandomized cohort of chlamydia screening among US Army recruits did not find a substantial reduction in the number of hospitalizations for PID. Data from historical cohorts have methodological limitations that restrict the capacity to make valid conclusions about the benefits of screening. Ecological studies have generally supported the effectiveness of chlamydia control programs in decreasing population-wide sequelae. However, because of coincident temporal changes in behavior, clinical practices, and rates of other infections, no firm conclusions can be drawn about the role of chlamydia screening in reducing complications, and it is impossible to assess benefit on an individual level.
Gaps in knowledge. At present, it is unknown whether findings similar to those observed in the randomized controlled trials reviewed here would be found in other populations possibly at lower risk, and it is also unclear whether the screening efforts implemented in these trials apply to screening programs currently in place. Perhaps most important, major gaps in knowledge include whether screening and treatment of asymptomatic, prevalent infection can prevent long-term sequelae, such as infertility and ectopic pregnancy-the outcomes we most want to prevent. Most of the studies we reviewed evaluated only 1-time screening, and there is little understanding of the overall benefits to an individual of 11 round of screening, the optimal frequency of screening, or the benefits of screening for recurrent infections [10] . In addition, the relative benefits of different types of screening approaches to prevent sequelae have not been evaluated. Finally, development of optimal screening strategies is limited by gaps in knowledge related to the natural history of C. trachomatis infection. For example, understanding the benefits of screening for infertility prevention depends in part on whether the pathologic processes leading to symptomatic PID (the main outcome in available trials) are the same as those leading to long-term outcomes. The effectiveness of a screening strategy also depends on the risk and timing of tubal damage relative to acquisition of infection and the mean duration of infection in the targeted population. Inaccurate measurement of the outcomes of chlamydial infection hampers our ability to evaluate screening strategies in both research and nonresearch settings.
Implications. Direct evidence about the effectiveness of finding and treating prevalent, asymptomatic chlamydial infection in preventing adverse sequelae clearly has major implications for chlamydia control efforts. Sequelae of chlamydial infection in a population can be prevented either by curing existing infections before they progress to PID and/or tubal damage or by preventing new C. trachomatis infections [28] . How a chlamydia control program should be structured, therefore, depends on the relative effectiveness of screening in reducing sequelae in infected women, compared with interrupting transmission and, thereby, reducing incidence in the population. Chlamydia screening has often been perceived as providing its main benefit through identification of women with chlamydial infection early enough to treat them and prevent progression to sequelae in those individuals [22] . This is the type of benefit that was evaluated in the trial by Scholes et al [12] . Until recently, cost-effectiveness analyses evaluating chlamydia screening as a way to prevent PID were structured around halting disease progression in already infected women rather than using screening as a tool to decrease transmission and prevent new infections in a population [29, 30] . A program focused primarily on reducing the number of sequelae in infected women makes the most sense if women with asymptomatic, prevalent infections still receive a substantial amount of benefit from treatment (ie, if tubal inflammation and damage would continue to be elicited beyond the time that a typical infection is detected by screening). However, if screening has little impact on preventing sequelae in infected women, because tubal damage, if it is to occur, happens relatively soon after the infection is acquired, control programs must focus primarily on reducing incidence of new chlamydial infection in the population. A program to reduce incidence of new infection in a population through interruption of chlamydia transmission might put greater emphasis, for example, on treatment of sex partners. Thus, more-precise estimates of the benefits of chlamydia screening to an individual infected woman may lead to consideration of new ways to optimally restructure chlamydia control programs to reduce adverse outcomes of chlamydial infection in a population.
Next steps and research needs. Additional studies of the effectiveness of detecting and treating asymptomatic, prevalent chlamydial infection in preventing sequelae would be useful. For countries that do not currently have an active chlamydia screening program in place as the standard of care, randomized controlled trials to better delineate the individual benefits of screening [12] could be done and would be valuable. Before the National Chlamydia Screening Programme was fully established in England, a randomized controlled trial of 1-time chlamydia screening among college-aged women was conducted and recently completed [31] . Published data from the trial were released too late for inclusion in this review but are available now [32] . Ideally, screening studies would collect data in a way that does not focus solely on prevention of PID in screened individuals, but also includes an assessment of communitywide benefits. Screening a group of women could reduce transmission in a population and, thus, prevent new infections, with their own attendant risk of sequelae, in women in the whole population.
Countries considering implementation of chlamydia screening programs have the opportunity to use randomization approaches, such as the stepped wedge design, to systematically evaluate the effects of screening, as is currently being done in the Netherlands [33] . In areas where screening for C. trachomatis infection is already recommended, assessments of the benefits of screening may be more challenging. However, additional creative approaches that make comparisons according to changes in screening intensity and coverage would add insight. Community randomization to evaluate the benefits of enhanced chlamydia screening efforts is currently being undertaken in Australia and provides an opportunity to collect valuable information (J. Hocking, personal communication). However, potential methodological problems need to be anticipated, including underlying baseline differences in community chlamydia prevalence, achieving high screening coverage, testing and treatment of sex partners, and accurate, unbiased ascertainment of outcomes.
A better understanding of the natural history of C. trachomatis infection is also essential to improving and informing chlamydia control efforts [3] . Ideally, natural history studies would help better clarify the incidence and timing of PID and tubal damage leading to long-term sequelae after untreated chlamydial infection. Such assessments would need to be done in different populations, including asymptomatic women with prevalent infection who have no indication for testing other than screening. Because it would be unethical to withhold treatment from a woman with known diagnosed infection and it is impossible to know when an infection was acquired when detected by screening, evaluations of the natural history of chlamydia will be difficult. However, studies that provide insight on some aspects of natural history may still be possible [34, 35] . Prospective studies that have obtained genital specimens for other reasons (eg, human papillomavirus natural history studies or vaccine trials and HIV prevention trials) should be explored as opportunities for better understanding chlamydia natural history, provided that study participants have given consent to test stored specimens and that chlamydia screening has been offered in accordance with standards of care. Additional natural history data on repeat infections would also be useful [3] , because these could help assess the importance of rescreening efforts. Ultimately, we would benefit from morespecific information about when treatment needs to be provided to prevent sequelae and whether treatment of long-standing prevalent infection has a tangible impact on complications. Better data on natural history would be helpful in modeling, shaping, and evaluating screening strategies in the context of a comprehensive chlamydia control program; such data would inform targeting of screening, the optimal frequency of screening, and resource allocation for screening women versus managing sex partners.
A critical component of research addressing chlamydia natural history and the impact of chlamydia screening is our ability to accurately measure the sequelae of C. trachomatis infection. We desperately need better, noninvasive tools to measure the complications of chlamydial infection. Diagnosis of acute PID is notoriously subjective, insensitive, and nonspecific [23, 36] . Infertility has multiple causes and may not be recognized for years after a chlamydial infection has caused tubal damage, because the affected woman may not have tried to become pregnant. Ectopic pregnancy is a more clear-cut diagnosis than is PID and infertility and could be more easily used in linking with administrative inpatient and outpatient data to assess outcomes. However, ectopic pregnancy is an uncommon outcome and its timing also depends on efforts or behaviors associated with becoming pregnant. Thus, ideally, we need tools not only to more accurately assess the sequelae observed as end-products (eg, PID, ectopic pregnancy, and infertility) but also to detect the intervening pathophysiologic processes leading to or predictive of those sequelae. More proximal, noninvasive markers of tubal damage would be extremely valuable for natural history and screening intervention studies and for candidate vaccine trials [37] . In addition, having the ability to predict individuals at increased risk of sequelae or reinfection could lead to targeting strategies that identify those who need, for example, more frequent screening or more intensive follow-up of sex partners. Thus, a better understanding of the immunologic, host, and organism factors underlying pathogenesis and sequelae and a search for relevant clinical markers could ultimately help guide targeted screening and control efforts [38, 39] .
